Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations
- PMID: 26575061
- DOI: 10.1001/jama.2015.14905
Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations
Abstract
Importance: Prostate cancer incidence in men 75 years and older substantially decreased following the 2008 US Preventive Services Task Force (USPSTF) recommendation against prostate-specific antigen (PSA)-based screening for this age group. It is unknown whether incidence has changed since the USPSTF recommendation against screening for all men in May 2012.
Objective: To examine recent changes in stage-specific prostate cancer incidence and PSA screening rates following the 2008 and 2012 USPSTF recommendations.
Design and settings: Ecologic study of age-standardized prostate cancer incidence (newly diagnosed cases/100,000 men aged ≥50 years) by stage from 2005 through 2012 using data from 18 population-based Surveillance, Epidemiology, and End Results (SEER) registries and PSA screening rate in the past year among men 50 years and older without a history of prostate cancer who responded to the 2005 (n = 4580), 2008 (n = 3476), 2010 (n = 4157), and 2013 (n = 6172) National Health Interview Survey (NHIS).
Exposures: The USPSTF recommendations to omit PSA-based screening for average-risk men.
Main outcomes and measures: Prostate cancer incidence and incidence ratios (IRs) comparing consecutive years from 2005 through 2012 by age (≥50, 50-74, and ≥75 years) and SEER summary stage categorized as local/regional or distant and PSA screening rate and rate ratios (SRRs) comparing successive survey years by age.
Results: Prostate cancer incidence per 100,000 in men 50 years and older (N = 446,009 in SEER areas) was 534.9 in 2005, 540.8 in 2008, 505.0 in 2010, and 416.2 in 2012; rates began decreasing in 2008 and the largest decrease occurred between 2011 and 2012, from 498.3 (99% CI, 492.8-503.9) to 416.2 (99% CI, 411.2-421.2). The number of men 50 years and older diagnosed with prostate cancer nationwide declined by 33,519, from 213,562 men in 2011 to 180,043 men in 2012. Declines in incidence since 2008 were confined to local/regional-stage disease and were similar across age and race/ethnicity groups. The percentage of men 50 years and older reporting PSA screening in the past 12 months was 36.9% in 2005, 40.6% in 2008, 37.8% in 2010, and 30.8% in 2013. In relative terms, screening rates increased by 10% (SRR, 1.10; 99% CI, 1.01-1.21) between 2005 and 2008 and then decreased by 18% (SRR, 0.82; 99% CI, 0.75-0.89) between 2010 and 2013. Similar screening patterns were found in age subgroups 50 to 74 years and 75 years and older.
Conclusions and relevance: Both the incidence of early-stage prostate cancer and rates of PSA screening have declined and coincide with 2012 USPSTF recommendation to omit PSA screening from routine primary care for men. Longer follow-up is needed to see whether these decreases are associated with trends in mortality.
Comment in
-
The Pendulum of Prostate Cancer Screening.JAMA. 2015 Nov 17;314(19):2031-3. doi: 10.1001/jama.2015.13775. JAMA. 2015. PMID: 26575059 No abstract available.
-
Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.Eur Urol. 2016 Jul;70(1):205-6. doi: 10.1016/j.eururo.2016.03.060. Epub 2016 Apr 18. Eur Urol. 2016. PMID: 27302292 No abstract available.
-
Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.J Urol. 2016 Apr;195(4 Pt 1):926-7. doi: 10.1016/j.juro.2016.01.053. Epub 2016 Jan 22. J Urol. 2016. PMID: 27302782 No abstract available.
-
Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.J Urol. 2016 Jul;196(1):105-6. doi: 10.1016/j.juro.2016.04.031. Epub 2016 Apr 13. J Urol. 2016. PMID: 27321505 No abstract available.
Similar articles
-
Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.Prostate. 2021 Oct;81(14):1071-1077. doi: 10.1002/pros.24204. Epub 2021 Jul 28. Prostate. 2021. PMID: 34320230
-
Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.Cancer. 2020 Feb 15;126(4):717-724. doi: 10.1002/cncr.32604. Epub 2019 Dec 3. Cancer. 2020. PMID: 31794057
-
Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.J Urol. 2018 Mar;199(3):676-682. doi: 10.1016/j.juro.2017.09.103. Epub 2017 Sep 28. J Urol. 2018. PMID: 28965781 Free PMC article.
-
Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.Curr Opin Urol. 2017 May;27(3):205-209. doi: 10.1097/MOU.0000000000000383. Curr Opin Urol. 2017. PMID: 28221220 Review.
-
The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.Nat Rev Urol. 2017 Jan;14(1):26-37. doi: 10.1038/nrurol.2016.251. Epub 2016 Dec 20. Nat Rev Urol. 2017. PMID: 27995937 Free PMC article. Review.
Cited by
-
A Provider-Facing Decision Support Tool for Prostate Cancer Screening in Primary Care: A Pilot Study.Appl Clin Inform. 2024 Mar;15(2):274-281. doi: 10.1055/s-0044-1780511. Epub 2024 Apr 10. Appl Clin Inform. 2024. PMID: 38599618
-
Urologists' and general practitioners' knowledge, beliefs and practice relevant for opportunistic prostate cancer screening: a PRISMA-compliant systematic review.Front Med (Lausanne). 2024 Feb 16;11:1283654. doi: 10.3389/fmed.2024.1283654. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38435387 Free PMC article.
-
Trends in the incidence and survival of cancer in individuals aged 55 years and older in the United States, 1975-2019.BMC Public Health. 2024 Jan 3;24(1):72. doi: 10.1186/s12889-023-17571-x. BMC Public Health. 2024. PMID: 38172749 Free PMC article.
-
Incidence trends in prostate cancer among men in the United States from 2000 to 2020 by race and ethnicity, age and tumor stage.Front Oncol. 2023 Nov 30;13:1292577. doi: 10.3389/fonc.2023.1292577. eCollection 2023. Front Oncol. 2023. PMID: 38098506 Free PMC article.
-
Race and Age-Related PSA Testing Disparities in Spinal Cord Injured Men: Analysis of National Veterans Health Administration Data.Fed Pract. 2023 Aug;40(Suppl 3):S50-S57. doi: 10.12788/fp.0392. Epub 2023 Aug 23. Fed Pract. 2023. PMID: 38021100 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous